Brokers see modest upside for CSL, but are very bullish on this smaller rival. The post Forget CSL shares, this ASX biotech ...

Journey Medical dermatology revenue plus Emrosi near-term sales and a rare pediatric disease PRV from Zycubo approval. See ...

FDA decision puts pelareorep in focus Oncolytics Biotech (NasdaqCM:ONCY) is back on investor radars after the FDA granted Fast Track Designation to pelareorep in a combination regimen for second line ...

Scholar Rock develops therapies for neuromuscular and oncological diseases, leveraging a proprietary platform to target unmet medical needs.

Over the past two calendar years, acquirers have agreed to pay more than $38 billion to purchase venture-backed companies in ...

Following strong earnings momentum in the fourth quarter of 2025, BB Biotech’s management is looking confidently at the year ahead.

Global drugmakers are stepping up their search for China‑developed experimental medicines as they cut costs ahead of patent ...

Goldman Sachs believes that Biohaven offers investors an under-the-radar opportunity to invest in a potentially best-in-class ...

Earlier in February 2026, Oncolytics Biotech announced that the FDA granted Fast Track Designation to pelareorep combined with bevacizumab and FOLFIRI for second-line treatment of KRAS-mutant, ...

Dr Reddy's Laboratories is strategically shifting focus towards biosimilars and innovation. The company is increasing investment in biosimilars, anticipating significant growth within five years.

Vertex has the revenue power to excel during any market environment.